scispace - formally typeset
D

Derek J. Parks

Researcher at Research Triangle Park

Publications -  55
Citations -  11718

Derek J. Parks is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Nuclear receptor & Receptor. The author has an hindex of 37, co-authored 55 publications receiving 11073 citations. Previous affiliations of Derek J. Parks include GlaxoSmithKline.

Papers
More filters
Journal ArticleDOI

Bile Acids: Natural Ligands for an Orphan Nuclear Receptor

TL;DR: Results provide evidence for a nuclear bile acid signaling pathway that may regulate cholesterol homeostasis and modulated interaction of FXR with a peptide derived from steroid receptor coactivator 1.
Journal ArticleDOI

Molecular Recognition of Fatty Acids by Peroxisome Proliferator–Activated Receptors

TL;DR: The peroxisome proliferator-activated receptors (PPARs) are nuclear receptors for fatty acids (FAs) that regulate glucose and lipid homeostasis as mentioned in this paper.
Journal ArticleDOI

Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands

TL;DR: It is demonstrated that several of the compounds that regulate mouse and human CAR, including natural steroids, bind directly to the receptors and suggest that CAR, like PXR, is a steroid receptor that is capable of recognizing structurally diverse compounds.
Journal ArticleDOI

Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition

TL;DR: The crystal structure of the human GR ligand binding domain (LBD) bound to dexamethasone and a coactivator motif derived from the transcriptional intermediary factor 2 is reported to establish a framework for understanding the roles of protein-hormone and protein-protein interactions in GR signaling pathways.
Journal ArticleDOI

6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity

TL;DR: 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.